Cargando…

Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden

BACKGROUND: The World Health Organization has set a goal to reach world elimination of hepatitis C virus (HCV) by 2030. Needle and syringe programs (NSP) for people who inject drugs (PWID) are crucial to achieve this goal. The NSP in Uppsala, Sweden, was opened in 2016 and has since 2018 provided HC...

Descripción completa

Detalles Bibliográficos
Autores principales: Kågström, E., Lannergård, A., El Khosht, J., Lörelius, P., Månflod, J., Strömdahl, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273738/
https://www.ncbi.nlm.nih.gov/pubmed/37328868
http://dx.doi.org/10.1186/s12954-023-00806-w
_version_ 1785059706757185536
author Kågström, E.
Lannergård, A.
El Khosht, J.
Lörelius, P.
Månflod, J.
Strömdahl, S.
author_facet Kågström, E.
Lannergård, A.
El Khosht, J.
Lörelius, P.
Månflod, J.
Strömdahl, S.
author_sort Kågström, E.
collection PubMed
description BACKGROUND: The World Health Organization has set a goal to reach world elimination of hepatitis C virus (HCV) by 2030. Needle and syringe programs (NSP) for people who inject drugs (PWID) are crucial to achieve this goal. The NSP in Uppsala, Sweden, was opened in 2016 and has since 2018 provided HCV treatment for PWID. The aim of this study was to investigate HCV prevalence, risk factors and treatment uptake and outcome in NSP participants. METHODS: Data from 450 PWID registered at the Uppsala NSP between 2016-11-01 and 2021-12-31 were collected from the national quality registry InfCare NSP. Data from the 101 PWID treated for HCV at the Uppsala NSP were collected through patient journal review. Descriptive and inferential analysis was performed. Ethical approval was obtained from the Ethical Review Board in Uppsala (dnr 2019/00215). RESULTS: The mean age was 35 years. 75% were males (336/450), and 25% were females (114/450). The overall HCV prevalence was 48% (215/450) with a declining trend over time. Factors associated with a higher risk of HCV were older age at registration (OR 1.025, 95% CI 1.004–1.046), lower age at injection drug debut (OR 0.963, 95% CI 0.932–0.996), lower education level (OR 1.829, 95% CI 1.185–2.821) and higher number of total visits at the NSP (OR 1.005, 95% CI 1.001–1.009). The overall HCV treatment uptake was 47% (101/215), of which 77% (78/101) completed HCV treatment. The HCV treatment compliance was 88% (78/89). 99% (77/78) were cured with a sustained virologic response 12 weeks after completed treatment. The reinfection rate over the study period was 9/77 (11.7%); all were male with mean age of 36. CONCLUSIONS: HCV prevalence, treatment uptake and treatment outcome have improved since the opening of the Uppsala NSP. However, further measures are needed to reach the HCV elimination goal. Outreach HCV treatment programs for PWID should be explored and evaluated in combination with further implementation of low-threshold programs.
format Online
Article
Text
id pubmed-10273738
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102737382023-06-17 Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden Kågström, E. Lannergård, A. El Khosht, J. Lörelius, P. Månflod, J. Strömdahl, S. Harm Reduct J Research BACKGROUND: The World Health Organization has set a goal to reach world elimination of hepatitis C virus (HCV) by 2030. Needle and syringe programs (NSP) for people who inject drugs (PWID) are crucial to achieve this goal. The NSP in Uppsala, Sweden, was opened in 2016 and has since 2018 provided HCV treatment for PWID. The aim of this study was to investigate HCV prevalence, risk factors and treatment uptake and outcome in NSP participants. METHODS: Data from 450 PWID registered at the Uppsala NSP between 2016-11-01 and 2021-12-31 were collected from the national quality registry InfCare NSP. Data from the 101 PWID treated for HCV at the Uppsala NSP were collected through patient journal review. Descriptive and inferential analysis was performed. Ethical approval was obtained from the Ethical Review Board in Uppsala (dnr 2019/00215). RESULTS: The mean age was 35 years. 75% were males (336/450), and 25% were females (114/450). The overall HCV prevalence was 48% (215/450) with a declining trend over time. Factors associated with a higher risk of HCV were older age at registration (OR 1.025, 95% CI 1.004–1.046), lower age at injection drug debut (OR 0.963, 95% CI 0.932–0.996), lower education level (OR 1.829, 95% CI 1.185–2.821) and higher number of total visits at the NSP (OR 1.005, 95% CI 1.001–1.009). The overall HCV treatment uptake was 47% (101/215), of which 77% (78/101) completed HCV treatment. The HCV treatment compliance was 88% (78/89). 99% (77/78) were cured with a sustained virologic response 12 weeks after completed treatment. The reinfection rate over the study period was 9/77 (11.7%); all were male with mean age of 36. CONCLUSIONS: HCV prevalence, treatment uptake and treatment outcome have improved since the opening of the Uppsala NSP. However, further measures are needed to reach the HCV elimination goal. Outreach HCV treatment programs for PWID should be explored and evaluated in combination with further implementation of low-threshold programs. BioMed Central 2023-06-16 /pmc/articles/PMC10273738/ /pubmed/37328868 http://dx.doi.org/10.1186/s12954-023-00806-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kågström, E.
Lannergård, A.
El Khosht, J.
Lörelius, P.
Månflod, J.
Strömdahl, S.
Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden
title Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden
title_full Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden
title_fullStr Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden
title_full_unstemmed Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden
title_short Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden
title_sort prevalence, risk factors, treatment uptake and treatment outcome of hepatitis c virus in people who inject drugs at the needle and syringe program in uppsala, sweden
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273738/
https://www.ncbi.nlm.nih.gov/pubmed/37328868
http://dx.doi.org/10.1186/s12954-023-00806-w
work_keys_str_mv AT kagstrome prevalenceriskfactorstreatmentuptakeandtreatmentoutcomeofhepatitiscvirusinpeoplewhoinjectdrugsattheneedleandsyringeprograminuppsalasweden
AT lannergarda prevalenceriskfactorstreatmentuptakeandtreatmentoutcomeofhepatitiscvirusinpeoplewhoinjectdrugsattheneedleandsyringeprograminuppsalasweden
AT elkhoshtj prevalenceriskfactorstreatmentuptakeandtreatmentoutcomeofhepatitiscvirusinpeoplewhoinjectdrugsattheneedleandsyringeprograminuppsalasweden
AT loreliusp prevalenceriskfactorstreatmentuptakeandtreatmentoutcomeofhepatitiscvirusinpeoplewhoinjectdrugsattheneedleandsyringeprograminuppsalasweden
AT manflodj prevalenceriskfactorstreatmentuptakeandtreatmentoutcomeofhepatitiscvirusinpeoplewhoinjectdrugsattheneedleandsyringeprograminuppsalasweden
AT stromdahls prevalenceriskfactorstreatmentuptakeandtreatmentoutcomeofhepatitiscvirusinpeoplewhoinjectdrugsattheneedleandsyringeprograminuppsalasweden